{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:44:04Z","timestamp":1790898244976,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008375","name":"University of Basel","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["OBES SURG"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Obesity, a chronic disease with serious associated medical problems, remains a global health challenge. While metabolic bariatric surgery (MBS) is the most effective treatment for weight loss, GLP-1 receptor agonists (RAs) are emerging as promising alternatives or adjuncts. This study evaluates the impact of preoperative GLP-1 therapy on weight loss and obesity-related complications over three years and explores reasons for transitioning to surgery.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Patients who underwent RYGB or SG from 2015\u20132021 were retrospectively analyzed, excluding those with revision and conversion surgeries, postoperative GLP-1 use, or pregnancy during follow-up. Propensity score matching (1:1) was used to adjust for confounders. The primary outcome was a combined endpoint of the SF-Bari Score, incorporating weight loss, improvement of obesity-related conditions, and surgical complications until 36\u00a0months post-surgery.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 215 patients were analyzed, including 54 who received GLP-1 RAs prior to surgery, with a preoperative total body weight loss (%TWL) of 3.7\u2009\u00b1\u20094.3%. %TWL did not differ significantly between groups: at 12\u00a0months, 29.8\u2009\u00b1\u20097.7% (non-GLP-1) vs. 28.1\u2009\u00b1\u20097.6% (GLP-1); at 24\u00a0months, 28.9\u2009\u00b1\u20098.2% vs. 27.2\u2009\u00b1\u20098.4%; and at 36\u00a0months, 26.9\u2009\u00b1\u20099.1% vs. 25.4\u2009\u00b1\u20099.1%. SF-Bari Scores were similar between groups at all timepoints: 96.0\u2009\u00b1\u200924.2 vs. 93.5\u2009\u00b1\u200926.3 at 12\u00a0months, 93.8\u2009\u00b1\u200924.4 vs. 91.0\u2009\u00b1\u200925.6 at 24\u00a0months, and 89.1\u2009\u00b1\u200924.7 vs. 85.5\u2009\u00b1\u200925.8 at 36\u00a0months (non-GLP-1 vs. GLP-1). Propensity score matching confirmed comparable outcomes between groups. Patients transitioned to surgery for definitive treatment, side effects, or medication unavailability.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Among patients who proceeded to surgery after GLP-1 therapy, prior GLP-1 use was not associated with different surgical outcomes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11695-025-08136-5","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T04:27:06Z","timestamp":1754972826000},"page":"3847-3857","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Surgical Outcomes in Patients with Preoperative GLP-1 Therapy: A Retrospective Analysis"],"prefix":"10.1007","volume":"35","author":[{"given":"Adisa","family":"Poljo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob J.","family":"Reichl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"B\u00fcrgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda S.","family":"Dirnberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romano","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Klasen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian T.","family":"Billeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beat P.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Peterli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Kraljevi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"8136_CR1","unstructured":"Obesity and overweight [Internet]. [cited 2024 Dec 28]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight"},{"key":"8136_CR2","unstructured":"World Obesity Federation [Internet]. [cited 2024 Dec 28]. Prevalence of Obesity. Available from: https:\/\/www.worldobesity.org\/about\/about-obesity\/prevalence-of-obesity"},{"issue":"8","key":"8136_CR3","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1056\/NEJMoa055643","volume":"355","author":"KF Adams","year":"2006","unstructured":"Adams KF, Schatzkin A, Harris TB et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med. 2006;355(8):763\u201378.","journal-title":"N Engl J Med"},{"issue":"8","key":"8136_CR4","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1056\/NEJMsr1606602","volume":"375","author":"B Lauby-Secretan","year":"2016","unstructured":"Lauby-Secretan B, Scoccianti C, Loomis D et al. Body fatness and cancer \u2014 viewpoint of the IARC working group. N Engl J Med. 2016;375(8):794\u20138.","journal-title":"N Engl J Med"},{"issue":"4","key":"8136_CR5","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40519-013-0049-4","volume":"18","author":"R Dalle Grave","year":"2013","unstructured":"Dalle Grave R, Calugi S, El Ghoch M. Lifestyle modification in the management of obesity: achievements and challenges. Eat Weight Disord. 2013;18(4):339\u201349.","journal-title":"Eat Weight Disord"},{"key":"8136_CR6","unstructured":"Perri MG, Corsica JA. Improving the maintenance of weight lost in behavioral treatment of obesity. In: Handbook of obesity treatment. New York, NY, US: Guilford Press; 2002. p. 357\u201379."},{"issue":"2","key":"8136_CR7","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/01.sla.0000133361.68436.da","volume":"240","author":"HJ Sugerman","year":"2004","unstructured":"Sugerman HJ, DeMaria EJ, Kellum JM et al. Effects of bariatric surgery in older patients. Ann Surg. 2004;240(2):243\u20137.","journal-title":"Ann Surg"},{"issue":"4","key":"8136_CR8","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1097\/XCS.0000000000000325","volume":"235","author":"N de la Cruz-Mu\u00f1oz","year":"2022","unstructured":"de la Cruz-Mu\u00f1oz N, Xie L, Quiroz HJ et al. Long-term outcomes after adolescent bariatric surgery. J Am Coll Surg. 2022;235(4):592\u2013602.","journal-title":"J Am Coll Surg"},{"issue":"15","key":"8136_CR9","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1016\/j.cell.2024.06.003","volume":"187","author":"CM Kusminski","year":"2024","unstructured":"Kusminski CM, Perez-Tilve D, M\u00fcller TD et al. Transforming obesity: the advancement of multi-receptor drugs. Cell. 2024;187(15):3829\u201353.","journal-title":"Cell"},{"key":"8136_CR10","unstructured":"Latif W, Lambrinos KJ, Patel P et al. Compare and Contrast the Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Dec 28]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK572151\/"},{"issue":"11","key":"8136_CR11","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002.","journal-title":"N Engl J Med"},{"issue":"11","key":"8136_CR12","doi-asserted-by":"publisher","first-page":"6560","DOI":"10.1007\/s00464-024-11191-1","volume":"38","author":"S Docimo","year":"2024","unstructured":"Docimo S, Shah J, Warren G et al. A cost comparison of GLP-1 receptor agonists and bariatric surgery: what is the break even point? Surg Endosc. 2024;38(11):6560\u20135.","journal-title":"Surg Endosc"},{"issue":"12","key":"8136_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003228","volume":"17","author":"ER McGlone","year":"2020","unstructured":"McGlone ER, Carey I, Veli\u010dkovi\u0107 V et al. Bariatric surgery for patients with type 2 diabetes mellitus requiring insulin: clinical outcome and cost-effectiveness analyses. PLoS Med. 2020;17(12): e1003228.","journal-title":"PLoS Med"},{"issue":"10","key":"8136_CR14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.41380","volume":"7","author":"K Lin","year":"2024","unstructured":"Lin K, Mehrotra A, Tsai TC. Metabolic bariatric surgery in the era of GLP-1 receptor agonists for obesity management. JAMA Netw Open. 2024;7(10): e2441380.","journal-title":"JAMA Netw Open"},{"issue":"12","key":"8136_CR15","doi-asserted-by":"publisher","first-page":"9509","DOI":"10.1007\/s00464-023-10387-1","volume":"37","author":"M Ilanga","year":"2023","unstructured":"Ilanga M, Heard JC, McClintic J et al. Use of GLP-1 agonists in high risk patients prior to bariatric surgery: a cohort study. Surg Endosc. 2023;37(12):9509\u201313.","journal-title":"Surg Endosc"},{"issue":"8","key":"8136_CR16","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.soard.2023.01.021","volume":"19","author":"JG Cunningham","year":"2023","unstructured":"Cunningham JG, Szoka N, Tabone LE et al. Preoperative and early adjuvant weight loss medications in bariatric surgery patients with body mass index over 60 or suboptimal initial response to surgery. Surg Obes Relat Dis. 2023;19(8):832\u201340.","journal-title":"Surg Obes Relat Dis"},{"issue":"5","key":"8136_CR17","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1002\/oby.23736","volume":"31","author":"N Murvelashvili","year":"2023","unstructured":"Murvelashvili N, Xie L, Schellinger JN et al. Effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery weight recurrence. Obesity. 2023;31(5):1280\u20139.","journal-title":"Obesity"},{"issue":"11","key":"8136_CR18","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1007\/s11695-018-3393-7","volume":"28","author":"P Rye","year":"2018","unstructured":"Rye P, Modi R, Cawsey S et al. Efficacy of high-dose liraglutide as an adjunct for weight loss in patients with prior bariatric surgery. Obes Surg. 2018;28(11):3553\u20138.","journal-title":"Obes Surg"},{"issue":"4","key":"8136_CR19","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s11695-023-06484-8","volume":"33","author":"AB Jensen","year":"2023","unstructured":"Jensen AB, Renstr\u00f6m F, Acz\u00e9l S et al. Efficacy of the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide for the treatment of weight regain after bariatric surgery: a retrospective observational study. Obes Surg. 2023;33(4):1017\u201325.","journal-title":"Obes Surg"},{"key":"8136_CR20","volume":"5","author":"V Mathur","year":"2025","unstructured":"Mathur V, Wasden K, Shin TH et al. Neoadjuvant Semaglutide, Bariatric Surgery Weight Loss, and Overall Outcomes. JAMA Surg. 2025;5: e250001.","journal-title":"JAMA Surg"},{"key":"8136_CR21","unstructured":"SMOB-Richtlinien-2023\u201307\u201301-Deutsch.pdf [Internet]. [cited 2024 Dec 26]. Available from: https:\/\/www.smob.ch\/wp-content\/uploads\/2024\/02\/SMOB-Richtlinien-2023-07-01-Deutsch.pdf"},{"issue":"3","key":"8136_CR22","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1001\/jamasurg.2023.6254","volume":"159","author":"R Peterli","year":"2024","unstructured":"Peterli R, Hurme S, Bueter M et al. Standardized assessment of metabolic bariatric surgery outcomes: secondary analysis of 2 randomized clinical trials. JAMA Surg. 2024;159(3):306\u201314.","journal-title":"JAMA Surg"},{"key":"8136_CR23","doi-asserted-by":"crossref","unstructured":"Bruinsma FFE, Hurme S, Peterli R et al. Validation of the Swiss-Finnish Bariatric Metabolic Outcome Score within a large prospective registry cohort. Br J Surg. 2025 May 31;112(6):znaf106.","DOI":"10.1093\/bjs\/znaf106"},{"key":"8136_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000006614","author":"SZ Aschen","year":"2024","unstructured":"Aschen SZ, Zhang A, O\u2019Connell GM et al. Association of perioperative glucagon-like peptide-1 receptor agonist use and postoperative outcomes. Ann Surg. 2024. https:\/\/doi.org\/10.1097\/SLA.0000000000006614.","journal-title":"Ann Surg"},{"issue":"9","key":"8136_CR25","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841\u201351.","journal-title":"N Engl J Med"},{"issue":"10193","key":"8136_CR26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330.","journal-title":"Lancet"},{"issue":"19","key":"8136_CR27","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"4","key":"8136_CR28","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"key":"8136_CR29","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.clnesp.2022.05.009","volume":"50","author":"C Stier","year":"2022","unstructured":"Stier C, Koschker AC, Kim M et al. Fast-track rescue weight reduction therapy to achieve rapid technical operability for emergency bariatric surgery in patients with life-threatening inoperable severe obesity - A proof of concept study. Clin Nutr ESPEN. 2022;50:238\u201346.","journal-title":"Clin Nutr ESPEN"},{"issue":"18","key":"8136_CR30","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1001\/jama.2023.19574","volume":"330","author":"M Sodhi","year":"2023","unstructured":"Sodhi M, Rezaeianzadeh R, Kezouh A et al. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA. 2023;330(18):1795\u20137.","journal-title":"JAMA"},{"issue":"8","key":"8136_CR31","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.14725","volume":"24","author":"JPH Wilding","year":"2022","unstructured":"Wilding JPH, Batterham RL, Davies M et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553\u201364.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"8136_CR32","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa1700459","volume":"377","author":"TD Adams","year":"2017","unstructured":"Adams TD, Davidson LE, Litwin SE et al. Weight and metabolic outcomes 12 years after gastric bypass. N Engl J Med. 2017;377(12):1143\u201355.","journal-title":"N Engl J Med"},{"key":"8136_CR33","first-page":"1","volume":"15","author":"N \u00c7al\u0131k Ba\u015faran","year":"2024","unstructured":"\u00c7al\u0131k Ba\u015faran N, Dotan I, Dicker D. Post metabolic bariatric surgery weight regain: the importance of GLP-1 levels. Int J Obes. 2024;15:1\u20136.","journal-title":"Int J Obes"},{"issue":"10","key":"8136_CR34","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.1007\/s11695-022-06211-9","volume":"32","author":"A Lautenbach","year":"2022","unstructured":"Lautenbach A, Wernecke M, Huber TB et al. The potential of Semaglutide once-weekly in patients without type 2 diabetes with weight regain or insufficient weight loss after bariatric surgery-a retrospective analysis. Obes Surg. 2022;32(10):3280\u20138.","journal-title":"Obes Surg"},{"issue":"1","key":"8136_CR35","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00423-023-02805-8","volume":"408","author":"JRM Colbourne","year":"2023","unstructured":"Colbourne JRM, Fisher OM, Mo S et al. The role of adjuvant pharmacotherapy with liraglutide for patients with inadequate weight loss following bariatric surgery. Langenbecks Arch Surg. 2023;408(1):115.","journal-title":"Langenbecks Arch Surg"},{"issue":"4","key":"8136_CR36","doi-asserted-by":"publisher","DOI":"10.1111\/cob.12323","volume":"9","author":"S Wharton","year":"2019","unstructured":"Wharton S, Kuk JL, Luszczynski M et al. Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post-bariatric surgery. Clin Obes. 2019;9(4): e12323.","journal-title":"Clin Obes"},{"issue":"6","key":"8136_CR37","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1111\/dom.13672","volume":"21","author":"M Suliman","year":"2019","unstructured":"Suliman M, Buckley A, Al Tikriti A et al. Routine clinical use of liraglutide 3 mg for the treatment of obesity: outcomes in non-surgical and bariatric surgery patients. Diabetes Obes Metab. 2019;21(6):1498\u2013501.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"8136_CR38","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2337\/db13-0511","volume":"63","author":"KM Habegger","year":"2014","unstructured":"Habegger KM, Heppner KM, Amburgy SE et al. GLP-1R responsiveness predicts individual gastric bypass efficacy on glucose tolerance in rats. Diabetes. 2014;63(2):505\u201313.","journal-title":"Diabetes"},{"issue":"6","key":"8136_CR39","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","volume":"389","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff AM, Kaplan LM, Fr\u00edas JP et al. Triple\u2013hormone-receptor agonist retatrutide for obesity \u2014 a phase 2 trial. N Engl J Med. 2023;389(6):514\u201326.","journal-title":"N Engl J Med"},{"issue":"6","key":"8136_CR40","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503\u201315.","journal-title":"N Engl J Med"}],"container-title":["Obesity Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11695-025-08136-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11695-025-08136-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11695-025-08136-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:42:06Z","timestamp":1758638526000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11695-025-08136-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["8136"],"URL":"https:\/\/doi.org\/10.1007\/s11695-025-08136-5","relation":{},"ISSN":["0960-8923","1708-0428"],"issn-type":[{"value":"0960-8923","type":"print"},{"value":"1708-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional Review Board"}},{"value":"Informed consent was obtained from all individual participants included in the.study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"Ethical approval was obtained from the Ethics Commission of Northwest and Central Switzerland (BASEC ID 2018-02093).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors have no conflicts of interest or financial ties to disclose.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}